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ABSTRACT
MOLECULAR SUBTYPING OF STAPHYLOCOCCUS AUREUS ISOLATES FROM
THE U.P. COMMUNITY FOR THE PRESENCE OF TOXIN-ENCODING GENES
By
Carol I. Kessel
Staphylococcus aureus is the most common cause of human bacterial infections;
however, humans can also be asymptomatically colonized with S. aureus. Asymptomatic
carriers can potentially spread S. aureus infection to others. These infections can range
from mild to severe. The pathology of a S. aureus infection is often dependent on which
toxins are expressed and the virulence factors with which they are associated. One goal of
this study was to isolate S. aureus from healthy, consenting adult volunteers who
submitted nasal swabs for culture and qRT-PCR analysis to determine which strains are
present in the community. This knowledge could potentially lead to more informed
treatment options when S. aureus infection is suspected. PCR-based subtyping was
utilized to test for the presence of fifteen toxin genes: lukAB, lukED, pvl, hlgA, hlgC, tst,
eta, hla, hlb, hld, sea, seb, sec, sed, and see. Isolates were also tested for the presence of
the mecA gene, which encodes for methicillin-resistant strains of S. aureus. Additionally,
nasal swabs were tested for the presence of Streptococcus pneumoniae by culture and
PCR by students in the Clinical Lab Sciences department. S. aureus and S. pneumoniae
can inhabit the nares in humans, although in vitro analysis indicated that S. pneumoniae
suppresses the growth of S. aureus. It was hypothesized that volunteers colonized with S.
pneumoniae will be less likely to carry S. aureus.
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Thirty-one strains of S. aureus were isolated from the nares of the volunteers,
resulting in a colonization rate of 21.9%. Each of the strains were positive for common
toxins, such as alpha and delta-hemolysins and hlgA/hlgC. Around half of the strains
were positive for the leukocidins LukAB and LukED, and a quarter were positive for
toxic shock syndrome toxin. Exfoliative toxin was not discovered in any of the strains.
Enterotoxins were discovered to be variant in presence depending on the type of
enterotoxin: sea had the highest prevalence at 32.26%, whereas see was absent from all
the isolates.
This study was the first to attempt to identify which genes were present across all
six classes of Staphylococcal toxins in community-colonized strains of S. aureus. We
have laid the path toward identifying what kind of S. aureus isolates are present in our
community. Further analysis using next-generation genome sequencing and spa typing
will need to be utilized to compare the community strains of S. aureus isolated in this
study to known disease-causing isolates from the hospital to discern if there is a
correlation between the two.
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CHAPTER ONE: INTRODUCTION TO STAPHYLOCOCCUS AUREUS AND
LITERATURE REVIEW

Staphylococcus aureus, an opportunistic pathogenic bacterium, is the most
common cause of bacterial infections in humans. S. aureus is a Gram-positive coccus
found on the skin and inside the nares of mammals. The name is a derivation of two
Greek words: “staphyle,” which means, “bunch of grapes,” and “kokkos,” meaning,
“berry,” named so for its shape and arrangement when observed under a microscope. The
bacteria was first discovered in 1880 by a Scottish surgeon by the name of Sir Alexander
Ogston, after he described “masses that looked like a bunch of grapes” within the pus
from a surgical abscess from a patellar joint 1. In 1884, another physician named
Friedrich Julius Rosenbach distinguished S. aureus from another similar species. It was
he who designated species names: “aureus” for the former, Latin for “gold”, and “albus”
for the latter, meaning “white” but was later changed to “S. epidermidis” due to its
likelihood of being found on the skin 1.
S. aureus is considered an opportunistic pathogenic bacterium due to its ability to
take advantage of damaged cutaneous layers. It can cause infections ranging from mild
skin irritation or a simple rash to severe illness including Toxic Shock Syndrome,
abscesses, bone infections, and sepsis. These bacteria are capable of wreaking havoc
within the human body, primarily by destroying red blood cells through the production of
hemolytic toxins 2 and causing sudden drops in blood pressure that can result in death. S.
aureus is the primary cause of lower respiratory tract and surgical site infections and is
the second leading cause of bacteremia, pneumonia, and cardiovascular infections 3.
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Furthermore, S. aureus can be found in undercooked food or improperly stored
food, and when ingested can cause serious cases of food poisoning 4. These illnesses are
caused by a family of toxins called enterotoxins, which are heat-resistant and therefore
quite difficult to remove from food once contaminated. Typically, foodborne illness
resulting from food contaminated with S. aureus is not life-threatening. Although it
causes a period of great discomfort, the infection is usually self-limiting within 24-48
hours.
All strains of S. aureus contain a thermonuclease enzyme commonly referred to
as Nuc, or NucA. It is a known virulence factor in invasive infections caused by S. aureus
as well as pneumonia caused by other strains of bacteria. Furthermore, NucA allows S.
aureus to evade neutrophil extracellular traps (NETs). NETs are webs of DNA released
by neutrophils in response to bacterial infection. Once neutrophils have become fully
functional, the nuclear material becomes condensed and segmented, allowing the cell to
essentially sacrifice itself and become a trap of sorts. Bacteria trapped in NETs are more
susceptible to lysis. Not only do NETs physically restrict the movement of the bacteria,
but the structure is studded with antimicrobial peptides (AMPs). AMPs can disrupt
bacteria cell membranes and induce lysis. NucA can degrade NETs in a similar fashion to
many other DNases5. Degradation of NETs would facilitate S. aureus escape from the
host immune system.
More recently, a nuclease-like homolog was discovered on the chromosome of S.
aureus, called Nuc2. A few studies have shown that Nuc2 is active in biochemical assays
but does not hold an important role in biofilm development like NucA does 5. However,
in most aspects the two are very similar as they are surface enzymes located on S. aureus
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with similar biochemical properties when studied in vivo and in vitro as studied by
Kiedrowski et al (2014). The presence of the gene that encodes for NucA is useful as a
control to determine that the strain in question is in fact S. aureus.
When speaking in terms of bacteria, “colonization rate” refers to the percentage of
people who have the bacteria growing as a part of their normal flora; this could be within
the nares, on the skin, or in the digestive tract, to name a few examples. In recent years,
the rate of colonization of S. aureus in the United States was approximately 32.4% 3.
Following colonization, S. aureus can also become a part of a person’s normal flora.
Most people colonized by S. aureus are asymptomatic, but this does not mean that these
bacteria do not have the potential to be dangerous. In fact, S. aureus carriage has a welldocumented correlation with infection rates in humans, with approximately 10-40% of
people tested upon admission to a hospital for a S. aureus infection are found to be nasal
carriers of the bacteria 6. If a host becomes immunosuppressed due to age, stress, disease,
or drug therapies for conditions such as organ transplants, asthma, and allergies, S.
aureus will likely cause an infection.
Historically, antibiotics from the beta-lactam family have always been used to
treat S. aureus infection. Beta-lactam antibiotics work by inhibiting cell wall synthesis,
and are commonly prescribed to treat infections caused by an array of Gram-positive and
Gram-negative bacteria. This class of antibiotics received its name due to the beta-lactam
ring that makes up their chemical structure. They include two highly-used antibiotic
families: penicillins and cephalosporins 7. S. aureus has the capability to produce betalactamases, which are enzymes that cleave the beta-lactam ring in the antibiotic structure,
rendering it useless 8.
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Before penicillin was approved for medical use and used as a treatment option for
S. aureus infections in 1940, the mortality rate for patients infected by the bacteria was
over 80% in a case study done at Boston City Hospital 9. It was only two years later that
the first strain of penicillin-resistant S. aureus was observed in a hospital and several
resistant strains were found within the community shortly thereafter. Within 20 years,
80% of known S. aureus strains were penicillin-resistant 10. A new antibiotic, methicillin,
was introduced in 1959 as a penicillinase-resistant penicillin with hopes for use to be able
to kill the newly resistant strains; however, by 1961 certain strains of S. aureus had
acquired a new gene, mecA, and became resistant to methicillin as well. This led to
various strains of S. aureus to evolve. Overuse of penicillins likely led to the selection of
Hospital-Associated Methicillin Resistant-S. aureus strains (HA-MRSA) as well as
several Community-Acquired Methicillin Resistant-S. aureus strains (CA-MRSA).
The primary difference between CA-MRSA strains and HA-MRSA strains is that
most CA-MRSA isolates contain the genes for the Panton-Valentine Leukocidin toxin
(pvl). The majority of CA-MRSA strains are susceptible to non-beta lactam antibiotics,
unlike HA-MRSA10. HA-MRSA strains tend to be resistant to several classes of
antibiotics commonly used to treat various infections. There is also a difference between
the two when looking at the type of staphyolococcal cassette chromosome mec (SCCmec)
element that is carried on the genome 11.
Although HA-S. aureus infections led to the selection of the first MRSA strains,
asymptomatic S. aureus carriers are presumably a reservoir for CA-S. aureus and can
potentially spread CA-MRSA to other people 12. During a surveillance period from July
2004 to December 2005, 8,987 cases of invasive MRSA infections were reported, and of
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those cases, 58.4% were community-onset infections 13. A second study performed in San
Francisco, California found that 90% of MRSA infections in the area during the same
time period had community-acquired onset 11. This has led to MRSA infections becoming
the most frequent cause of skin and soft tissue infections that are presented in the ER in
the United States to date. Furthermore, approximately 20% of bloodstream infections are
caused by S. aureus.
As previously stated, methicillin-resistant strains of S. aureus are resistant to
Penicillin antibiotics (also known as Beta-lactams) due to presence of a gene called
mecA. The mecA gene encodes Penicillin Binding Protein 2a (PBP2a), a transpeptidase
that helps build the S. aureus cell wall 14. PBP2a has low binding affinity for Betalactams. The presence of PBP2a can therefore allow S. aureus to continue building cell
walls even in the presence of these antibiotics. These strains of S. aureus have become
endemic in many United States hospitals, long-term care facilities, and communities 15.
Although many analysts would assume that HA-MRSA strains spread into communities
to generate new CA-MRSA strains, data seems to show that the transmittance of the
mecA gene may in fact be the other way around.
Currently, vancomycin is the drug of choice to treat MRSA infections. This
antibiotic has a low chemotherapeutic index, which means that the line between
therapeutic levels and toxicity is very narrow. The therapeutic range at trough level (a
level drawn right before the first dose of the day is administered) is only between 10.020.0 mcg/ml 16, compared to broad-spectrum antibiotics which have a much higher
chemotherapeutic index, and are therefore less dangerous to the patient. As of 2010, nine
strains of vancomycin-resistant S. aureus (VRSA) have been reported in the United
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States 17. The majority of strains of S. aureus that are VRSA strains are also resistant to
methicillin; however, a strain of VRSA that was methicillin sensitive was discovered in
2015, which begins a new series of questions about how quickly S. aureus can develop
resistance 18. As of now, there are few treatment options available to combat VRSA
infections.
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CHAPTER TWO: THE INTERACTION BETWEEN STAPHYLOCCOCUS
AUREUS AND STREPTOCOCCUS PNEUMONIAE

Like S. aureus, Streptococcus pneumoniae is an opportunistic pathogen. S.
pneumoniae is a Gram-positive lancet-shaped diplococcus, is encapsulated by a
polysaccharide layer for protection, and is alpha-hemolytic 19. S. pneumoniae can cause a
range of diseases including middle ear infections (otis media), sinus infections,
meningitis, pneumonia, and bacteremia 20. The bacterium is most likely to colonize in the
upper respiratory tract in humans, especially in children. Colonization rates are highest in
childhood, with a peak rate around 55%; they slowly drop off as the child ages until the
percentage stabilizes around 8% at the age of 10 and on through adulthood 21.
Pneumococcal infections are extremely dangerous and often deadly if contracted by
patients who are immunocompromised, elderly, or children. In the United States, the
mortality rate caused by pneumococcal infections is approximately 40,000 people a year
21

. Of those, approximately 18,000 are older adults (>65 years of age), as traditional

treatment methods with penicillin-type drugs and other antibiotics are not always
effective due to the newly resistant strains of S. pneumoniae 22.
Colonization by S. pneumoniae in the nares is mostly asymptomatic, again like S.
aureus. However, S. pneumoniae may progress to disease in immunodeficient patients,
and colonization by the bacteria leads to person-to-person transfer of different strains to
other members of the population. Pneumococcus bacteria are spread from one host to
another through droplet-transmission such as coughing, sneezing, or close contact with
the bodily fluids of an infected individual 20. It is recognized that children pose the
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greatest risk for person-to-person transfer of these strains to one another; this means the
current standard course of action is to focus on prevention of pneumococcal nasal
carriage in children.
S. aureus and S. pneumoniae compete with one another: that is, they are rarely
found co-colonized within the nares of one host. It is hypothesized that this is due to the
hydrogen peroxide production by S. pneumoniae – it is toxic in vitro to other bacteria,
including S. aureus 23. The interaction between S. pneumoniae and several other common
nasal-colonizing bacteria such as Haemophilus influenzae and Moraxella cattarrhalis
have been studied in experiments in which the bacteria were co-cultured. In each case, S.
pneumoniae had an inhibitory effect on the other bacteria, with the exception of Neisseria
meningitidis, which appeared to thrive in the presence of the pneumococcal bacteria 21.
A study by Gili Regev-Yochay et al. in 2006 observed a linear relationship
between the inoculum level of S. pneumoniae and death rate of S. aureus. No killing of S.
pneumoniae by S. aureus was observed throughout the course of the experiment. When
catalase was added to a co-culture of S. pneumoniae and S. aureus, death rates of S.
aureus significantly decreased. This is intriguing because S. aureus naturally produces
catalase, yet seems to be extremely susceptible to the effects of hydrogen peroxide. This
could be due to the inability of S. aureus to combat an initial large dose of hydrogen
peroxide that is released by S. pneumoniae in vitro, although no conclusive data has been
published on the exact mechanism to date. One study found that in parallel to a decrease
in S. pneumoniae colonization rate with age, a simultaneous increase of S. aureus
carriage is apparent 21.
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There is a conventional vaccine that is commercially available aimed to reduce
disease caused by S. pneumoniae disease: Prevnar. Prevnar is a pneumococcal
polysaccharide vaccine that is offered in several different forms, depending on the age of
the patient. The first vaccine was licensed in the United States in 2000 and named
Prevnar-7 as it protected against seven serotypes of S. pneumoniae 24. In 2010, an
updated vaccine was licensed in the United States that protected against an additional six
serotypes, and was subsequently named Prevnar-13. Prevnar-13 is now part of the typical
vaccination schedule used by pediatric and family medicine clinics in children ages 23
months and younger 25.
The current schedule indicates that Prevnar-13 is to be given concurrently with
other childhood vaccines at 2, 4, 6, and between 12-15 months of age 25. Before the
vaccination became routine, the United States saw approximately 13,000 of cases of
septicemia, 700 cases of meningitis, and around 200 deaths in children under 5 years of
age each year due to S. pneumoniae. Since the vaccine has been added to the commercial
vaccination schedule for children, these incidences have decreased by approximately
88% 22.
The vaccination is highly effective and an important step towards lowering the
rate of preventable mortalities in the high-risk groups outlined above. However, it is
hypothesized that by vaccinating to reduce the colonization of S. pneumoniae, we are in
turn increasing the likelihood of S. aureus carriage. This has been observed in a
population study from 201226 (Figure 1).
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It is important to examine which strains of S. aureus are colonizing in the nares of
the general public as well as which toxins genes these strains are carrying in order to
determine their potential pathogenicity.

40%

Percent Carriage of S. aureus
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25%
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20%

24 months
20%

14%

15%
10%
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8%

5%

7%
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0%
PRE-PCV7

3 YEARS POST-VACCINE 4.5 YEARS POST-VACCINE

Figure 1: Timeline of Prevnar and the start of the increase in S. aureus carriage. This
figure shows data from a study by Spijkerman et al (2012) where carriage rates of S.
aureus were compared with vaccination status of children. Nasal carriage rates were
measured before, 3 years after, and 4.5 years after introduction of Prevnar vaccine in
children at 11 and 24 months of age, and in parents of 24 month old children. Aside
from a 1% decrease in carriage of the 24 month old group, it is clear that there was an
increase in S. aureus colonization rate after introduction of the vaccine.
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CHAPTER THREE: COMMON TOXINS AND THEIR ASSOCIATED GENES
EXPRESSED BY STAPHYLOCOCCUS AUREUS

S. aureus can cause a wide variety of diseases that range greatly in terms of
severity. Examples include simple skin lesions such as pimples/boils, to much more
severe including systemic blood and/or bone infections, Toxic Shock, pneumonia, and
deep tissue abscesses 2,3,15. The severity of infection is often dependent on which toxin
genes are present, and the virulence factors associated with them. Five classes of toxins
were examined in this study: leukocidins, enterotoxins, exfoliative toxin, toxic shock
syndrome toxin, and hemolysins.
One of the sub-goals of this thesis research was to determine which types of toxin
genes are present in the nasal colonizing S. aureus strains found within Upper Peninsula
community. By being aware of which strains are present in the community, a better
understanding of the virulence factors can be determined, which in turn may aid local
physicians in providing more informed treatment for suspected S. aureus infections.

Leukocidins
Leukocidins are a type of exotoxin that consist of two synergistic classes of
proteins, class S (slow) and class F (fast) 27. These toxins work by first activating human
neutrophils to travel to the infection site and begin the healing process. The toxins then
form holes in the cell membranes of the neutrophils 13, which damage the host cell and
lead to tissue destruction and cell death. Leukocidins can target several different types of
mammalian cells, including monocytes, macrophages, and red blood cells 28. The
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severity of the symptoms resulting from intoxication increases dramatically when these
toxins are present. Typically, S. aureus infections that are associated with leucocidin
producing strains result in furuncles, pneumonia, and some types of diarrhea.
The leukocidins genes targeted in this study were pvl, lukAB, lukED, hlgA, and
hlgC, specifically. These toxins are commonly found in CA-MRSA strains. Pvl is
encoded by two genes in particular, lukFPV and lukS-PV 27. These genes code for the
proteins, LukFPV and LukSPV, that work synergistically to damage membranes of host
cells including erythrocytes and host defense cells 29. The production of pvl has been
linked to severe wound infections, including furuncles, cutaneous abscesses, and
necrosis. Pvl production is associated with high morbidity rates, and is known to be an
important virulence factor in CA-MRSA, whereas HA-MRSA strains do not typically
carry the pvl gene 11.
HlgA and HlgC are class S proteins that are encoded as a gamma hemolysin. hlgA
constitutes a single open reading frame, but hlgC (and another similar toxin, not tested for
in this study, hlgB) are co-transcribed. LukED is comprised of two separate genes, lukE
and lukD, and is found on a locus that co-transcribes both S class and F class proteins.
LukAB is the most commonly expressed and secreted leukocidin, yet it was only
discovered in 2011 30. This toxin specifically targets the plasma membrane of the host
cell and has a particular affinity for destroying human neutrophils31. If the bacterium is
phagocytized before lukAB is able to destroy the neutrophils, the toxin facilitates escape
from the phagosome by perforating the phagosome via pores until it ruptures, freeing the
bacteria 31.
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Exfoliative Toxin
Exfoliative toxins (ET) cause Staphylococcal Scalded Skin Syndrome (SSSS), a
disease which creates blisters that cover the skin leaving it irritated, red, peeling, and
painful 32. SSSS typically affects infants, and is especially dangerous for this age group
due to the comorbid factors that result in the loss of superficial skin layers such as
dehydration and secondary infections.
There are two known ET genes, eta and etb, although for the purposes of this
study only eta was examined. According to current literature, approximately 80% of
exfoliative toxin-encoding S. aureus strains have the eta gene, rather than etb 33, therefore
it was determined that searching for eta only would suffice for the purposes of this study.
ET’s are serine proteases around 30 kDa in size that are very specific, in that they only
cleave cadherins in superficial layers of the skin, but do not affect the deeper layers of the
dermis and subdermis 33. Cleavage of cadherins results in weepy, raw, red skin; however,
as usually only superficial skin layers are affected, this rarely results in a scar. Recent
reports show that approximately 3-4% of methicillin-susceptible strains of S. aureus carry
either the eta or the etb gene, whereas about 10% of MRSA strains carry eta.

Enterotoxins
A second class of toxins is a part of a group called pyrogenic toxin superantigens
(PTSAgs), a group that also includes toxic shock syndrome toxin. Enterotoxins effect the
digestive system and are commonly the cause of food poisoning related to S. aureus
contamination in undercooked foods. The enterotoxins found in S. aureus are heat stable
and cannot be removed from food through heating, making them especially dangerous 2.
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Food poisoning that occurs due to S. aureus contamination usually consists of nausea and
vomiting symptoms that occur within a few hours of ingestion but are self-limiting within
a day or two. Staphylococcal food poisoning also typically results in intense intestinal
peristalsis, which results in severe abdominal cramping. From 1998 to 2010, 570
confirmed outbreaks caused by S. aureus enterotoxins were recorded by the Centers for
Disease Control and Prevention (CDC), resulting in 8,015 illnesses and 406
hospitalizations 34.
Eight staphylococcal enterotoxin groups have been recognized to date: sea, seb,
sec, sed, see, seg, seh, and sei 34. Each are small peptide chains of approximately 26 to 29
kDa in length, and are very similar at the amino acid level, with around 51-81% sequence
similarity 14,35. It takes a very small amount of enterotoxin to cause foodborne
intoxication – for example, a study has shown that the dose required to produce vomiting
was approximately 5-20 g per animal 35. In this study, the genes that were specifically
examined were sea, seb, sec, sed, and see. These five genes were chosen specifically
because they are the five classified as emetic types, rather than having an “other”
classification. There is less certainty about the functions of seg, seh, and sei and what
type of illness they cause in mammalian models. The enterotoxins fall into two clades:
sea-see, for example, fall into clade I, meaning they are closely related to the
streptococcal toxins, whereas the latter group are in clade II, and are therefore more
distantly related 35.
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Toxic Shock Syndrome Toxin
The aforementioned Toxic Shock Syndrome (TSS) is a serious condition that
results in a sudden, sharp drop in blood pressure that can result in death 4. The rapid drop
in blood pressure is due to the ability of the TSS to cause host immune cells to release
large amounts of potent vasodilating cytokines 13. TSS can crosslink T-cell receptors to
the MHCII receptors on the surface of antigen presenting cells (APCs). This process
occurs even in the absence of antigens and causes a massive overstimulation of both
APCs and T-cells. This then generates a cytokine storm that results in a fever, rash,
shock, and progressive multiple organ failure 36. Data shows that TSS does not have a
greater prevalence within any specific age groups; it is often found in previously healthy,
young patients. In the 1980s, a link was recognized between TSS and menstruation/
tampon usage in women 37. A tampon saturated with blood is a supportive place for rapid
growth of bacteria, including S. aureus, which is often present in the vagina as normal
flora. The insertion and removal of a tampon can cause microscopic tears in the walls of
the vaginal canal, allowing the bacteria to enter the bloodstream. Since this discovery,
there has been a warning on tampon boxes to caution women against improper use to
reduce the risk of TSS.
TSS has been clinically shown to be associated with S. aureus strains that express
the Toxic Shock Syndrome Toxin (tst) 4. In previous studies, approximately 14% of
community strains that were tested were positive for tst alone, however the gene seemed
to have high comorbidity levels with enterotoxins such as sea, seb, and sec as well 4. A
study in 1990 determined that a single clone of S. aureus accounted for 88% of cases of
TSS in the study group 38.
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Hemolysins
A final class of toxins called hemolysins will rupture red blood cells within the
host. One hemolysin in particular, -hemolysin (Hla), binds to a receptor that has been a
well-studied virulence factor for the past century but was only identified within S. aureus
in recent years. -Hemolysin binds to the cell surface and forms a pre-pore as the
monomers assemble, later transitioning into a -barrel transmembrane pore that allows
ions (such as 𝐾 + and 𝐶𝑎2+ ) to enter through an aqueous channel, leading to cell death via
lysis 39.
A second type, -hemolysin (Hlb), does not form pores in the plasma membrane,
instead acting by using enzymatic activity to result in hemolysis. Beta-hemolysis has
been observed to be highly hemolytic in some animal models, such as sheep, but less
hemolytic in other models such as rabbits 40 It has been observed that red blood cells are
only lysed after the temperature is lowered, which suggests that the lytic activity is not
quite as efficient as -hemolysin 39. This phenomenon has been referred to as “hot-cold”
hemolysis, and has been studied extensively in sheep blood 41.
As previously mentioned, a third type, -hemolysin, belongs to a group of genes
that code for both hlgA and hlgC as the S (slow) component, or hlgB as the F (fast)
component. -Hemolysin works in a similar fashion to PVL, by allowing water-soluble
components to bind to the cell surface as a monomer, then oligomerizing into a prepore,
and finally transforming in to a hetero-octamer with four S components and four F
components 39. These molecules then form a -barrel transmembrane pore that crosses
the plasma membrane and leads to lysis by the host cell.
The hemolysins examined at in this study were hla, hlb, and hld.
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CHAPTER FOUR: EXPERIMENTAL DESIGN AND METHODS

Sample Collection & Preparation
The first step of the experimental design was to obtain an approved Application
for Review of Research Involving Human Subjects from the NMU Institutional Review
Board (Appendix A). After approval was secured, four separate volunteer sample
collections were set between June 2015 and October 2015. At each collection date,
healthy, consenting adult volunteers self-swabbed each nostril after signing a consent and
filling out the questionnaire provided (Appendix B). The samples were collected by the
author and/or several undergraduates/faculty and were labeled with an accession number.
The swabs were streaked on blood agar (Hardy Diagnostics) and then stored in MuellerHinton broth tubes (Remel) and labeled with the corresponding accession. Blood agar
plates were incubated for 18-24 hours at 37 degrees Celsius before further analysis.
Mueller-Hinton broth tubes were incubated for 18-24 hours at 37 degrees Celsius before
DNA extraction was performed.

Identification of S. aureus
The blood plates were screened for any beta-hemolytic bacteria that looked like it
could be S. aureus: i.e. round, white-to-golden colonies with entire margins. Strains that
appeared to be S. aureus were re-streaked for isolation on blood agar, and incubated for
another 18-24 hours at 37 degrees Celsius. Once verifying isolated, beta-hemolytic
colonies were present, the strains were streaked on Mannitol Salt Agar (VWR Scientific)
to test for mannitol fermentation (Figure 2). S. aureus is capable of fermenting mannitol,
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a type of sugar, which decreases the pH of the media by releasing acetic acid and lactic
acid byproducts. A decrease in pH results in the neutral red dye in the media to change
color from pink to yellow.

2A

2B

2C
Figure 2: Biochemical tests used to identify isolated strains as S. aureus. (A) shows
a sheep blood agar plate with beta-hemolysis. (B) shows a negative (1) and a
positive (2) Staphaurex test. Agglutination shows the presence of coagulase and
Protein A found in S. aureus. (C) depicts a positive and negative MSA plate. The
yellow color change of agar is the result of mannitol fermentation, and is an
indicator of S. aureus.
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Samples that fermented mannitol were then further tested using Staphaurex
(Remel), a biochemical solution that contains latex particles coated with human
fibrinogen and IgG that is used to look for the presence coagulase and Protein A,
respectively 42. Coagulase and Protein A are proteins found on the surface of S. aureus
cells. The positive presence of S. aureus causes an agglutination reaction of the latex
beads present in the Staphaurex solution. Genomic DNA was extracted from all bacterial
isolates that were beta-hemolytic, mannitol fermenting, and Staphaurex positive.
Genomic DNA isolation was performed using the QIAamp DNA mini spin kit (Qiagen),
essentially as described in the manufactures protocol. Genomic DNA quality and
concentration were measured using a NanoDrop spectrophotometer (Thermofisher).
Isolated genomic DNA was tested for the presence of nucA using quantitative
polymerase chain reaction (qRT-PCR) to verify that the strains were in fact S. aureus
before testing for toxins. NucA is used as the marker for verification of S. aureus because
it is a thermonuclease enzyme found in all strains of this bacterial species. While the
presence of nucA is found in a few other staphylococcal species, species-specific primers
for S. aureus were used to detect the presence of the target bacteria in this study.

DNA Extraction
All mannitol-fermenting, Staphaurex positive strains were used to create 5 ml
overnight cultures using tryptic soy agar (TSB) as the medium (Hardy Diagnostics). After
incubation overnight at 37 degrees Celcius, the cultures were centrifuged at 4000x
gravity for 10 minutes. Following centrifugation, the supernatant was removed, and
genomic DNA was extracted from the bacterial cell pellet. The QIAamp DNA mini spin
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kit was used per manufacturer’s protocol to extract the S. aureus DNA, as well as to
extract DNA from all positive control strains (Table 1) and from a lab strain of
Pseudomonas aeruginosa (PAO1) that was used as a negative control throughout the
experiment.
Table 1: Control strains of S. aureus and P. aeruginosa used in this study. The S.
aureus control strains used in this study were obtained from BEI Resources. MRSA
strain BAA 1763 was acquired from the ATCC. PAO1 was obtained from the Dove
lab, Boston’s Children’s Hospital
Strain Name

Positive Control for:

Negative Control for:

A860325

seb, hla, hld

N/A

A950206

sed, hla, hlb, hld, lukED

N/A

A970675

hla, hld, eta

mecA

FRI 913

tst, sea, sec, see

mecA

HFH-30032

pvl, mecA

N/A

HFH-30106

mecA

pvl

HT 20020233

mecA, seb

N/A

HT 20020320

mecA, sea, sed, lukED

N/A

MNHOCH

seb

mecA

MN8

tst

N/A

USA300

lukAB, hlgA, hlgC, mecA

N/A

WKZ-1

eta, tst

N/A

1078

mecA, pvl

tst, enterotoxins

BAA 1763

MRSA strain for plate assays

N/A

FRI913
PAO1

Methicillin sensitive strain for plate
assays
Negative DNA control for all S.
aureus toxin genes
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N/A
N/A

Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR)
Most of the toxin genes targeted in this study already had qRT-PCR primers that
had been previously published (Table 2). The Primerquest Real-Time PCR primer design
program was used to design the primers for lukAB, as they had not been previously
published. Primers were ordered from idtDNA.
Table 2: Primer sets used in this experimental design for qRT-PCR.
Target
Forward Primer
Reverse Primer
Gene
eta
hla
hlb
hld
hlgA
hlgC
lukAB
lukED
mecA
nucA
pvl
sea
seb
sec
sed
see
tst

TGC ATT GAC ACC ATA GTA
CT
CTG ATT ACT ATC CAA GAA
CTT TCC AGC CTA CTT TTT
ATT CGA TTG
TAT CAG T
TGA AGA TGG TGG CGT AGC
TCA TGT CCA GCA CCA CAA
GAT TGT
CGA GAA
AAG AAT TTT TAT CTT AAT
TTA GTG AAT TTG TTC ACT
TAA GGA AGG AGT G
GTG TCG A
AAT CGG AGG CAG TGG CTC
GGA CCA GTT GGG TCT TGT
ATT CAA
GCA AAT
TCG GTG GTA ATT TCC AAT
CGA ATG AAT TCG CTT TGA
CAG CCC
CGC CC
CGT GGA GCG TTA ACT GGA
ACA CCT TTA TGT GAC GTA
AAT A
GAT TGA
GAA TGG CCA AAT CAT TCG
GAA ATG GGG CGT TAC TCA AA
TT
GCA ATC GCT AAA GAA CTA
GGG ACC AAC ATA ACC TAA
AG
TA
GCG ATT GAT GGT GAT ACG
AGC CAA GCC TTG ACG AAC
GTT
TAA AGC
GCT CAA CAT ATC ACA CCT
AAG TGG GTT GGG TAT AGC
GTC AGC GA
CTG AGT
AAG TGC CGA TCA ATT TAT
CCT GAA CAG TTA CAT TTT
GGC TA
TCT TAT TCG T
AGA AAA AGG TGA CTG CTC
CGT TTC ATA AGG CGA GTT
AAG AAT
GTT
GCT CAA GAA CTA GAC ATA
CCT GGT GCA GGC ATC ATA T
AAA GCT AGG A
GAG TTT GAT TCT TCT GAT
AAG GTG CTC TGT GGA TAA
GGG TCT AA
TGT TTT
ATA ACT TAC CGT GGA CCC
GCT TTG GCG GTA AGG TGC
TTC AGA
TTT TTA TCG TAA GCC CTT TGT TAT TAT CGT TTG TAG ATG
TG
CTT TTG C
CTA GTG CAT TTG TTA TTC AA
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The first set of qRT-PCR runs were used to identify that nucA was present in all
strains and to verify that the strains were all in fact S. aureus. The FastStart Essential
DNA Green Master kit (Roche) was used following manufacturer’s protocol (Table 3),
with annealing conditions that differed for each of the specific toxin gene primer sets.
Table 3: qRT-PCR reaction mix components used in the experimental design
DNA

5 l [≈5ng/l]

Primer

2 l [20 g/l]

RNase-free H20

3 l

SYBR Green Mix

10 l

The PCR cycle conditions that were used consisted of a hot start at 95 degrees
Celsius for 600 seconds, followed by 35 cycles of denaturing at 95 degrees Celsius for 10
s, annealing (temperature dependent on primer used – see Table 4) for 15 s, and extension
at 72 degrees Celsius for 10 s. This was followed by melt curve analysis. The
LightCycler 96 (Roche) and software were used for the qPCR runs and analysis.
Table 4: Annealing temperatures used for each primer set. The annealing temperatures
listed below were determined using the suggested annealing temperatures listed on the
package insert for each primer set from idtDNA.
Annealing
Annealing
Primer Set
Primer Set
Temperature
Temperature
eta
mecA
45C
50C
hla

55C

sea

55C

hlb

60C

seb

55C

hld

55C

sec

55C

hlgA

57C

sed

55C

hlgC

57C

see

57C

lukAB

60C

tst

54C

lukED

54C

pvl

60C

nucA

55C
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Further Analysis of mecA Positive Strains
If a strain tested positive for the mecA gene with qRT-PCR, secondary
biochemical testing was used to verify the results were of a resistant phenotype. TSB agar
plates (Hardy Diagnostics) supplemented with 4 g/ml oxacillin (VWR Scientific) were
streaked with a positive mecA strain (BAA1763) and a methicillin-sensitive strain
(FRI913). If growth was present, the result was deemed positive for oxacillin resistance
(Table 5). Oxacillin is used because methicillin is not commercially available any longer,
and oxacillin holds its reactivity well even during long periods of storage.
Table 5: Interpretations of Oxacillin minimum inhibitory concentration. These values
are adapted from the CDC classification of S. aureus sensitivities to methicillin.

Staphylococcus
aureus

Susceptible

Intermediate

Resistant

≤ 2 μg/ml

N/A

≤ 4 μg/ml (MRSA)

A second test was performed on Mueller-Hinton agar (Remel) using Cefoxitin
discs (Thermofisher) placed using the Kirby-Bauer method. If the zone of inhibition was
≤ 21 mm, the result was deemed positive for Cefoxitin resistance (Table 6). Cefoxitin is
most commonly used to detect methicillin resistance because it is a great inducer of
mecA, and results in clear zones of inhibition that make it easy to analyze results.
Table 6: Cefoxitin disc zone of inhibition classification for MRSA.

Staphylococcus
aureus

Susceptible

Intermediate

Resistant

≤ 25 mm

N/A

≤ 21 mm
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Antibiotic Sensitivity Testing of mecA Positive Strains
S. aureus strains that contained the mecA gene, grew on oxacillin agar, and were
cefoxitin resistant were sent to UP Health Systems Marquette to further identify and test
for antibiotic sensitivity. A colony of S. aureus was suspended in saline and pipetted into
a Gram-positive identification/sensitivity plate panel called Pos Combo type 34
(Beckman Coulter). The plate was incubated and read in a Microscan Walkaway 96 plus
instrument (Beckman Coulter).
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CHAPTER FIVE: RESULTS

Volunteer Population
Of the 141 volunteers, 55 were male (39%) and 86 were female (61%). Of the
males, 10 were colonized with S. aureus (18.18%) whereas 18 females were colonized
(20.93%). Like most studies, these findings suggest that gender does not seem to be a
factor in S. aureus carriage. As for age, carriage rates do not seem to be statistically
significant (Table 7).
Table 7: S. aureus carriage rates based on age. Of the 141 total volunteers sampled, the
age brackets and carriage rates are listed below to show rates of colonization.
Number of
Number of
Colonization Rate
Age
volunteers
positive isolates
Percentage
18-30 years

87

17

19.54%

31-40 years

15

6

40.00%

41-49 years

6

1

16.66%

50-59 years

16

3

18.75%

60-69 years

7

0

0.00%

75+ years

10

1

10.00%

Typically, bacterial colonization rate studies do not find a correlation between age
and carriage rate. This is because bacteria that colonize in healthy noses are just looking
for a host that is well enough to aid in the spreading of the bacteria, so therefore age is
not typically a factor.
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Assessment of Toxin Gene Presence within the Isolates
There were 31 total strains collected and identified as S. aureus after the four
collections. Each of the strains were positive for nucA as determined by two replicates of
qPCR using USA300, WKZ-1, and FRI 913 as positive controls (all positive controls
contain the nucA gene, as they are all S. aureus species), and PAO1 as the negative
control. Positive signals were seen between 11-16 cycles, also known as the Ct value
(Figure 3). A Ct value just refers to the cycle at which fluorescence starts to increase
exponentially. Melt curves analysis was used to assess that only the product of interest
was amplified, as seen by a single peak around one melting temperature point: multiple
peaks would indicate contamination or non-specific amplification.
Figure 3:
LightCycler 96
analysis of nucA.
(A) Shows a melt
curve analysis.
(B) shows an
amplification
curve. Although
the colors are
difficult to
discern, positive
signal Ct values
fell within 11-16
cycles. The PAO1
and negative
controls are
represented by
the flat line at the
bottom.

A

B

Of the 16 toxin genes tested for in the study, 13 were present within the
community-found strains (Figure 4). Three of the toxin genes (pvl, eta, and see) were not
found within any of the collected strains.
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15014
15017
15019
15020
15031
15037
15039
15049
15057
15061
15071
15088
15107
15108
15111
15119
15123
15125
15126
15129
15130
15131
15150
15154
15157
15167
15169
15172
15174
15176
15178
mecA

pvl

lukED

lukAB

tst

hla

hlb

hld

sea

seb

sec

sed

see

eta

hlgA

hlgC

Figure 4: Stacked bar graph showing which strains of S. aureus contained which
toxins. Some toxins were represented in higher numbers than others, with some toxins
(i.e. eta) not represented within the strains at all. Note that the length of the bars is
arbitrary, and the bar colors depict the presence of a particular toxin.

The leukocidins group had varying results. Zero of the 31 isolated S. aureus
strains tested positive for pvl, therefore none contained Panton-Valentine leukocidin
(Figure 5A). As for lukED, 13 of 31 (41.94%) were positive (Figure 5B). The presence of
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lukAB was even higher, with 17 of 31 (54.84%) strains positive for the gene (Figure 5C).
Furthermore, toxic shock syndrome toxin was present in 25.81% of the strains, with 8 of
31 containing the tst gene (Figure 5D).
Figure 5: Example
melt curve analyses as
determined through
analysis by the LC96
software. (A) shows
the melt curve for pvl,
which only had signal
in the positive control
group, no other strains
had the toxin present.
(B) depicts the melt
curve of lukED, with
the green signals being
the positive control
and other colors
showing several of the
strains tested in that
particular run. (C) is
set up similar to B,
however C depicts
lukAB signals. (D)
shows the melt curve
for tst, again with the
green lines depicting
the positive controls,
and other colors to
show the strains in that
run that were positive
for tst.

A

B

C

D

The hemolysins were, as expected, highly present within the strains. Both hla and
hld were present in 100% of the strains (Figures 6A and 6C), whereas hlb was slightly
lower, at 27 of 31 (87.10%) strains (Figure 6B). hlgA and hlgC (Figures 6D and 6E) were
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both present in 100% of the strains as well. eta, unsurprisingly, was not present in any of
the strains (Figure 6F).

A

D

B

E

C

F

Figure 6: Example melt curve analyses as determined through analysis by the LC96
software. (A) shows the melt curve obtained for hla, a hemolysin present in every
strain of S. aureus. (B) depicts the melt curve for hlb, which is a hemolysin found in
slightly fewer percent of community strains. (C) depicts hld presence, which is 100%,
similar to hla. (D) shows the melt curve obtained in one of the runs for hlgA, which is
again found in every strain of S. aureus. (E) shows one of the qPCR runs for hlgC,
also present in 100% of S. aureus strains. (F) shows the melt curve analysis for eta,
which was not present in any toxin. The green shown is the signal by the positive
control used, WKZ-1.

The enterotoxins had the highest variation of levels of presence within the strains.
The highest prevalence belonged to sea with 10 of 31 (32.26%) of strains being positive
for the gene (Figure 7A). Seb had only 1 of 31 (3.23%) present (Figure 7B), and sec had
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2 of 31 (6.45%) positive for the gene (Figure 7C). Sed was present in 1 of the 31 strains
(3.23%) (Figure 7D), but see was not present in any of the strains (0 of 31) (Figure 7E).

Figure 7: Example melt
curve analyses as
determined through analysis
by the LC96 software. (A)
shows the melt curve for
sea, which was the most
commonly detected of the
five enterotoxins. (B)
depicts the melt curve of
seb, with the green signals
being the positive control
and the blue signal showing
the other strain that tested
positive for the toxin. (C)
shows the signals for sec,
again with the green
depicting the positive
control and the fuschia
showing the two other
signals detected. (D) shows
the melt curve for sed, again
with the green lines
depicting the positive
controls, and fuschia
showing the other positive
signal detected by the one
positive community strain.
(E) shows the melt curve
analysis for see, which only
had signals for the positive
control: no community
strains tested positive for
this enterotoxin.

A

B

C

D

E
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Figure 8 shows a breakdown of what percentages of each toxin was present within
the 31 total strains of S. aureus.

100%

100% 100% 100%

100.00%

87.1%

90.00%

80.00%

70.00%

60.00%

54.8%

50.00%
41.9%
40.00%
32.3%
30.00%

25.8%

20.00%

10.00%

6.5%
3.2%

3.2%
0%

3.2%
0%

0%

0.00%

Figure 8: Percentages of each toxin gene and mecA present within the 31 strains of S.
aureus. Percentages are shown above each bar.

Methicillin-Resistant Strains
Of the 31 strains of S. aureus isolated from the nares of volunteers within the
community, only one strain (15031) was positive for mecA. This strain was further tested
using Cefoxitin discs and Oxacillin (Figure 9). After testing positive with growth present
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on the Oxacillin field plate as well as growth within the parameters set in Table 5 (see
previous chapter), it was determined that strain 15031 was likely methicillin-resistant S.
aureus, and was sent to the UPHS-Marquette microbiology laboratory for further testing.

A

B

Figure 9: Biochemical tests used to verify strains were methicillin-resistant.
Strains were further tested after discovering the mecA gene via qPCR. (A) shows
the Oxacillin plate test. Each quadrant is labeled: FRI 913 refers to a mecA
negative control, and shows no growth. BAA1763 is the positive control strain,
and shows growth, therefore oxacillin-resistance. Strain 15031 was the mecA
strain of S. aureus. (B) shows the Cefoxitin disc test, with the same controls used.
Strains 15031L and 15031R had clearings of 14 mm and 13 mm, respectively.
This is a positive result for resistance to Cefoxitin, a marker for methicillin
resistance.

Each of the bacterial strains that required further testing was sent to the UPHSMarquette laboratory streaked on agar plates. After analysis, the laboratory sent printouts
of the results of antibiotic sensitivity testing that was performed, as well as the names of
any identifiable bacteria, including the control strains (Figure 10). The control strains sent
were BAA1763 and FRI913. Strain 15031 was determined to be methicillin-resistant
(Figure 11).
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A

B

Figure 10: Antibiotic sensitivity test results. (A) shows the positive control strain for
mecA that was sent to UPHS-Marquette, BAA1763, with the result in line one showing
that it is in fact Methicillin Resistant Staphylococcus aureus. (B) was the negative
control for mecA that we supplied the lab, FRI913 (methicillin-sensitive S. aureus).
The result in line one verifies that it is in fact methicillin sensitive Staphylococcus
aureus.
Figure 11:
Antibiotic
sensitivity test
results of the
mecA
community
strain. After
analysis, it was
determined (line
1) that the strain
was in fact
methicillinresistant S.
aureus
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Staphylococcus haemolyticus Strain
An unusual strain (labeled as “15026”) was originally identified as S. aureus, as it
was mannitol fermenting and beta-hemolytic, but it was not nucA positive, nor positive
for Staphaurex. This strain also tested positive for mecA, so it was sent to the UPHSMarquette hospital lab as well for further analysis using the same techniques previously
described. The strain in question was determined to be Staphyloccocus haemolyticus
(Figure 12). S. haemolyticus is a coagulase-negative staphylococci (CoNS) species that is
closely related to S. aureus. S. haemolyticus is known for its high levels of resistance to
many antibiotics, including methicillin. The same mecA gene is present on the
staphylococcal cassette chromosome mec element (SCCmec) as the gene found in S.
aureus 49.

B

A

Figure 12: Lab analysis printout of S. haemolyticus strain. (A) shows a screenshot of
the printout from the hospital lab after analyzing the mecA positive, but nucA negative
community strain (15026) that was sent to them. After analysis, it was determined (line
1) that the strain was S. haemolyticus and not a strain of S. aureus. (B) shows the
results of the cefoxitin disc test that shows resistance to the antibiotic with clearings
measuring 15 mm (15026 L1) and 14 mm (15026 L2).
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S. haemolyticus is associated with nosocomial infections, especially within the
immunocompromised, including neonates 50, but it is not commonly found as a colonized
strain within the nares of a healthy adult. This strain of S. haemolyticus was not included
in the analysis in Figure 4 due to being a different species of Staphylococcus spp. While
some of the toxin genes are similar in S. aureus and S. haemolyticus, there are definite
genetic differences. Our qRT-PCR primers were species-specific by design to target for
S. aureus specific genes, so this could have given us false-negative results when testing
for genes that we know are usually present in S. haemolyticus, such as nucA.

Mannitol Non-Fermenting Strain
Another unusual strain was discovered within the collection samples, 15111. This
strain presented as S. aureus because it had a typical S. aureus appearance on blood agar:
round, yellow colonies that were beta-hemolytic. Strain 15111 also tested positive for
both nucA and Staphaurex; however, it was mannitol non-fermenting – that it, although
the strain grew on MSA agar, it did not produce the typical yellow pigment seen due to
mannitol production. This strain was sent to the UPHS-Marquette laboratory for further
testing, and was determined that it was a strain of S. aureus that was mannitol nonfermenting (Figure 13). According to Joe Levandoski, microbiology supervisor at UPHSMarquette, less than 4% of S. aureus strains tested in our area are mannitol nonfermenting, which means that they do not contain the genes for mannitol fermentation.
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A

B
Figure 13: Further analysis of the mannitol non-fermenting strain of S. aureus. In
line one (A), it is verified that the strain was in fact S. aureus, but biochemical
testing on MSA agar showed no mannitol fermentation (bottom half of plate), as
compared to the positive control strain (top half of plate) (B). (C) shows how this
strain was resistant to beta-lactam antibiotics. The strain on the left in the photos is
a negative control, FRI 913, and the strain on the right is 15111. The zones of
inhibition were, from top to bottom: carbenicillin (FRI 913: 36 mm, 15111: 15
mm), penicillin (FRI 913: 37 mm, 15111: 0 mm), and ampicillin (FRI 913: 35 mm,
15111: 10 mm).
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CHAPTER SIX: DISCUSSION & CONCLUSION

This study was the first to attempt utilizing qRT-PCR to identify which genes
were present within community-colonizing strains of S. aureus. Five classes of
Staphylococcal toxins (leukocidins, hemolysins, enterotoxins, toxic shock syndrome
toxin, and exfoliative toxins) as well as methicillin-resistance were studied. Previous
studies focused mainly on one or two of the classes at a time. Moreover, similar previous
studies have focused primarily on hospital strains of the bacteria isolated after causing
infection, or on strains found in contaminated foods. This study is important because it
examined patterns of toxin carriage in isolates that have not previously been examined.
Due to the nature of this study being a comprehensive report of all the different toxin
types and their presence, several interesting combinations of toxin genes (or lack thereof)
were discovered upon analysis.
A study by Mehrotra et al. (1999) looked at healthy human colonizing strains, and
found that of 107 isolates tested, 24.3% had the tst gene 14. This study showed similar
findings, with 25.81% of the strains tested containing the gene. Interestingly, out of every
strain of S. aureus that carried the tst gene, none of them also had the gene for any of the
leukocidins. One study that detected the presence of toxic shock syndrome toxin along
with the enterotoxins and exfoliative toxins found that tst presence is symptomatically
related to enterotoxins, but there is no mention of its relationship with leukocidins 4. Cocarriage of these two classes of toxins is not well-studied. It can be proposed that for a
nasal colonizing strain of S. aureus, it might be disadvantageous to carry a toxin that
works locally, like a leukocidin, as well as a systemic toxin, like tst. A strain carrying
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both could potentially be extremely virulent and may cause in an aggressive infection,
whereas it is more advantageous for nasal colonizing strains to be less virulent.
The study mentioned above found that 14% of the strains they tested contained
only tst, 50% had tst in conjunction with sea, 11% had tst and seb, and 25% had tst and
sec 4. Comparatively, this thesis study found 13% of the strains contained only tst, and
another 13% contained tst alongside sea. No strains presented with tst and any of the
other four enterotoxins. These findings suggest that the presence of tst is not mutually
exclusive with the presence of enterotoxins, and follows the same proposal suggested in
previous studies that many healthy individuals can carry toxin-producing strains of S.
aureus 14,51.
Within this study, there was a 100% prevalence for hlgA and hlgC. This is
unsurprising as hlgA, hlgB, and hlgC are the most abundant extracellular proteins on S.
aureus as identified in recent studies 52.
The lukAB gene was found in 54.8% of the strains isolated in this study, whereas
lukED was only present in 41.9%. Interestingly, if a strain had the lukED gene, it copresented with lukAB as well. However, lukAB was found without the presence of lukED.
LukAB is one of the more prevalent leukocidins found in community strains of S. aureus
30

, although the discovery of the toxin is so recent, there is much less data on lukAB

carriage rates in S. aureus. Two strains (15037, 15071) co-carried both lukAB and sea
(6%). One strain (15131) was positive for both lukAB and seb (3%), another strain
(15126) was positive for both lukAB and sec, and a third strain (15154) was positive for
both lukAB and sed. Unfortunately, a study comparing the prevalence of lukAB with other
toxins has yet to be published due to the relatively recent discovery of lukAB. It can be
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hypothesized that due to the high prevalence of LukAB in S. aureus, this leukocidin can
be found co-carried with several other toxins. This is another example of why this study
was so important in looking at the patterns in toxin carriage.
Panton-Valentine leucocidin was not present in any of the strains. This is not a
particularly surprising finding, as Pvl is usually found in severe infections, so one would
not expect nasal colonizing strains to be positive for Pvl. A study by Prevost et al. (1995)
found only 2% of the strains tested contained Pvl 53,54. However, the S. aureus strains
tested in Prevost’s study were isolated from aggressive skin infections, rather than the
healthy nares of healthy members of a community.
The enterotoxins were found in a small percentage of strains, but this was
expected as the strains were colonized from the nares, not from the gut. In addition, it
was determined that no two enterotoxins were present together. With 32% of the strains
positive for sea, only a handful of strains were positive for either seb (3%), sec (6%), or
sed (3%), and no strains contained see. The study by Mehrotra et al. (1999) found
approximately 20% of the strains tested contained sea, 6% were positive for seb, 7%
positive for sec, and 2% positive for sed; this study similarly found that no strains were
positive for see 14. These findings, that enterotoxin positive S. aureus colonizers are so
commonly found in the nose, reinforce how important it is to follow food-safety
regulations, such as wearing gloves and abiding by proper cooking/storage regulations.
These proteins function not only as gastrointestinal toxins, but as superantigens:
they stimulate T-cell proliferation in the mammalian body 35. As these two functions are
located on two separate domains, they have different physiologic targets. Each of the
enterotoxins are found in different locations on a prophage, and the prophages only carry

39

one type of enterotoxin 55. In some instances, a plasmid can carry more than one type of
enterotoxin at a time, but this is rarely observed. Additionally, most of the enterotoxins
are found at a single locus in the S. aureus genome, making inheritance of more than one
enterotoxin gene at a time very rare. Together, this may explain why we only found one
type of enterotoxin, if any, in each strain of S. aureus isolated in this study.
Every strain out of the 31 collected was positive for both the hla and hld genes
(100%), whereas only 27 of 31 strains were positive for hlb (87%). Comparatively, a
study by Abdalrahman and Fakhr (2015) had similar findings: 97.7% of the strains
isolated from chicken livers were positive for both hla and hld, and only 64.4% were
positive for hlb 2. These findings make sense because hla and hld are typically found
together 56.
Zero of the isolated community strains were positive for eta, although this finding
is unsurprising. Several studies have had negative results for exfoliative toxin when
testing strains of S. aureus isolated from food or nasal passages 2,4,14. Due to the severely
infectious nature of strains that carry exfoliative toxins, one would not expect to find
those virulent strains within the nares of an otherwise healthy host, similar to the
expectations for Pvl.
Of the nasal isolates in this study, only one strain (15031) out of the 31 isolates
was identified as methicillin-resistant (3.23%), aside from the one strain of methicillinresistant S. haemolyticus. Literature shows that between 1.5-2% of the healthy, adult
population is colonized for MRSA in the nares 57. Out of the 141 total volunteers, this
means there was MRSA colonization in only 0.7% of the population. Although slightly
low compared to previously published literature, the sample size in this study was not
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very large, so the percentages could be slightly higher. Further collections would need to
be performed to gather a larger sample size.
While the work studying S. pneumoniae carriage was carried out in the CLS
department and is not currently complete, it might be a good idea to consider the
possibility of developing a vaccination against colonization by S. aureus if a correlation
is found between S. aureus and S. pneumoniae carriage. In a study by Karauzum et al.
(2013), they examined the possibility of developing attenuated LukS and LukF mutants
as a vaccine possibility to defend against virulent S. aureus infection 58. They reported
successful development of two mutants that protected from lethal bacteremia caused by
infecting mice with a CA-MRSA strain, USA300. Vaccination against Pvl seems to lead
to decreased virulence in mice. Therefore, Pvl might be a useful vaccine candidate
against extremely virulent strains of S. aureus. However, since Pvl is not carried by a
high percentage of S. aureus strains, it would not likely function as a universal S. aureus
vaccine.
A second study focused on developing a vaccine candidate based on the Hla
toxin, which may be the better direction to go in due to the high prevalence of Hla (i.e. it
was present in every strain of S. aureus in this study) 59. The vaccine candidate was called
AT-62aa, and was designed based on the heptameric crystal structure of Hla. It was tested
in mice against pneumonia and bacteremia infection models using the Newman and
USA300 strains of S. aureus, and showed high levels of protection in each model. A third
study was focused on developing a vaccine specific to MRSA infection, but as Hla is a
very important virulence factor in MRSA, this study focused on inducing high anti-Hla
titers 60. Results indicated that the vaccine inhibited lesion formation at the site of
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infection. It was also successful at reducing the invasiveness of MRSA by preventing the
spread of infection into other organs.
Interestingly, hla is also carried by some other pathogentic Staphylococcus
species like S. haemolyticus. One study found that approximately 92% of S. hameolyticus
isolates also carried hla61. There is about 2-5% difference in nucleic acid sequence
between the hla gene carried by S. aureus and S. haemolyticus. It is currently unknown if
a S. aureus hla vaccine would generate an antibody response that is cross-protective to S.
haemolyticus infection. However, due to the high carriage rate of hla in S. aureus, hla
seems very promising as a vaccine target. A general S. aureus vaccine could be useful in
at-risk patients such as the elderly, the immunocompromised, or those with frequent skin
diseases including infection by S. aureus or MRSA.
It is important to mention that more than one strain of S. aureus was isolated from
some volunteers in this study, as we swabbed both nostrils. These strains were denoted by
an ‘R’ or an ‘L’ to differentiate in which nostril the strain was discovered. Upon analysis,
the same toxin gene was always found in each strain for the volunteer, which suggests
that the strains were clonal. The spa gene (codes for the S. aureus-specific staphylococcal
protein A) has a higher level of polymorphism, and is more useful in discerning whether
or not two strains are clonal 2. S. aureus isolates that have an identical or similar spa gene
are more likely to be clonal or more closely related. To identify whether the strains in my
study isolated from different nostrils are truly clonal, further spa typing would be an
important next step. There are worldwide databases that have records of the spa types
from various MRSA outbreaks and other S. aureus studies. It would be interesting to see
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how related S. aureus isolates from the U.P. community are to those in other parts of the
United States or world.
In the future, we hope to develop a stronger understanding of the virulence of S.
aureus strains present in our community. The next plan for this project is to use next
generation sequencing to sequence the genomes of several of the strains collected, and
compare them to several S. aureus isolates from the hospital that are currently causing
disease in the community. We could compare the toxin gene and the antibiotic resistance
gene carriage between the two different groups of S. aureus. We could then study their
genetic similarities and differences. This data could help develop an idea of how closely
related the nasal colonizing strains are to disease-causing strains, and may give us key
insights into S. aureus biology. Together, this data could help address the question
regarding disease-causing probabilities of community strains.
To take it a step further, the genomic sequences of these strains can be compared
to the national databases on S. aureus strains to hopefully gain a better understanding of
how S. aureus spreads amongst humans. Overall, this study was one of the first to lay a
roadmap toward understanding the difference between community strains of S. aureus
and disease-causing strains, and as a result, can help to develop better options for not
only the treatment, but the prevention of potentially fatal S. aureus infections.
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D.
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APPENDIX B

Volunteer Informed Consent Statement

The Study
You are invited to be in a research study entitled, The relationship between methicillinresistant S. aureus nasal colonization and vaccination with a pneumococcal conjugate
vaccine in adults”. The goal of this study is to explore whether vaccines that prevent
pneumonia alter nasal flora of adults. This study is being conducted by Dr. Yuba Gautam,
Dr. Paul Mann, Dr. Josh Sharp, Catherine Bammert, and graduate students Carol Kessel,
Melissa Pierpont and Polly Hockberger from NMU. Up to 100 participants will be asked
to be in this study.
Free to Choose
You are free to choose whether or not to be in this study. You may refuse to answer any
questions you do not wish to answer. You may withdraw in part or in full from this study
at any time without any ill will or penalty.
What to Expect
If you consent to participating in this research, you will be asked to complete a
questionnaire which will take about 10 minutes of your time. You will also be asked to
collect a swab from each of your nostrils. This process should take no more than 5
minutes.
Because we are an academic and not a certified or accredited, clinical laboratory,
we are not legally allowed to share information with you regarding the bacteria we
grow from your nasal swab.
Confidentiality
Your answers will remain anonymous. All raw data will be stored away from this consent
form in a locked file drawer. Only the principle investigators listed above will have
access to the data from this study. If the data is published, your name will not be linked to
the data.
Additionally, the Northern Michigan University Institutional Review Board and federal
reviewers may access our research data to review our research processes, if deemed
necessary. In very rare cases, loss of confidentiality may occur if a court orders that
research files or information be submitted as evidence in a legal matter.
Risks and Benefits
If you are uncomfortable collecting your nasal swab in an open area, we will make an
accommodation to find a private area so that you will be more comfortable. While the
risks associated with collecting a nasal swab are minimal, you may experience minor
discomfort.
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Your participation in this study will increase our knowledge regarding the relationship
between vaccines that prevent pneumonia and the composition of nasal bacteria.
Questions about the Study
Please let us know now if you have any questions about this study. You may contact the
researchers, as follows: Paul Mann (pmann@nmu.edu), Josh Sharp (jsharp@nmu.edu),
Yuba Gautum (ygautam@nmu.edu), or Cathy Bammert (cabammer@nmu.edu).
Questions about Your Rights
If you have any questions about your rights as a research subject you may contact the
NMU IRB Administrator, Dr. Brian Cherry, Assistant Provost of Graduate Studies and
Research at Northern Michigan University 001-906-227-2300 or bcherry@nmu.edu.
I have read or the above informed consent has been read to me. The nature of risks,
demands, and benefits of the project were made clear to me. I know that I may ask
questions. I know I am free to withdraw from the project at any time without having any
ill will or penalty. I also know that this informed consent sheet will be kept away from
the project data to maintain confidentiality. Only the principle investigators or an
authorized representative will have access to this consent statement. A copy of this
consent statement will be given to me.

_____________________
Please print your name

_______________________
Please sign your name

__________________
Date

I have taken care to explain the nature of the above project to the subject. I hereby
confirm that to the best of my knowledge, the subject signing the informed consent form
clearly understands the nature, risks, and demands of being a subject in this study. A
language barrier, health problem, or other barriers have not precluded a clear
understanding of his or her involvement in this project.

_____________________________
Name

_________________
Date

Thank you for your participation in this research study!
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APPENDIX C

Volunteer Questionnaire
Q1. Age
❍
❍
❍
❍
❍
❍

18-30 years
31-40 years
41-49 years
50-59 years
60-69 years
75 years and above

Q2. Gender
❍ Male
❍ Female
❍ Other

Q3. Race/Ethnicity
❍
❍
❍
❍
❍
❍

White
Hispanic or Latino
Black or African American
Native American or American Indian
Asian or Pacific Islander
Other

Q4. Have you ever had frequent skin infections?
❍ Yes
❍ No
❍ Not Sure

Q5. Have you ever had frequent eye, nose, and throat infections?
❍ Yes
❍ No
❍ Not Sure
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Q6. Have you ever been diagnosed with S. aureus or MRSA infection?
❍ Yes
❍ No
❍ Not Sure

Q7. Have you ever been diagnosed with S. pneumoniae infection?
❍ Yes
❍ No
❍ Not Sure

Q8. Do you have history of cancer, bone marrow, organ transplant, or
immunosuppressive condition?
❍ Yes
❍ No
❍ Not Sure

Q9. Do you have a history of recent or frequent hospitalization?
❍ Yes
❍ No
❍ Not Sure

Q10. Have you ever been treated with antibiotics in the last 3 months? If yes, what
kind of antibiotics?
❍ Yes
❍ No
❍ Not Sure

List antibiotics: _____________________

55

Q11. Have you been given the Pneumococcal vaccine? If so, do you know if it was
the Prevnar vaccine?
❍
❍
❍
❍

Yes
No
Not Sure
Prevnar Yes__________, No ___________, Not Sure _________

Q12. I have read the inform consent. I am willing to participate in this study and
give consent for a Nasal Swab.

Signature of the participant: _________________________________
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APPENDIX D

Table of CT Values for Positive Signal of Toxins Obtained from This Study
Gene

Run
Collection
One, 1st run
Collection
One, 2nd run

nucA

mecA

Collection
Two, 1st run
Collection
Two, 2nd run
Collection
Three, 1st run
Collection
Three, 2nd run
Collection
Four, 1st run
Collection
Four, 2nd run
Collection
One, 1st run
Collection
One, 2nd run
Collection
Two, 1st run
Collection
Two, 2nd run
Collection
Three, 1st run
Collection
Three, 2nd run
Collection
Four, 1st run
Collection
Four, 2nd run

CT Values Observed
12.1, 12.7, 13.3, 12.9, 12.3, 12.8, 14.1, 13.2, 34.2, 31.1,
11.7, 11.0, 13.4, 11.8, 13.7, 13.2, 13.6, 13.6, 13.1, 11.8,
11.3
12.0, 12.6, 13.3, 13.0, 12.9, 12.8, 14.1, 13.3, 34.2, 31.2,
12.0, 11.6, 13.3, 12.0, 13.7, 13.4, 13.7, 13.7, 13.4, 11.4,
11.3
15.1, 16.3, 14.9, 14.9, 13.4, 15.0, 14.9, 13.5, 11.9, 11.2,
11.4, 11.6, 11.5
15.2, 16.3, 14.9, 14.9, 13.4, 15.2, 15.1, 13.4, 12.0, 11.0,
11.4, 11.6, 11.5
16.0, 15.0, 17.1, 13.3, 15.5
16.1, 15.3, 16.0, 13.4, 15.3
13.0, 13.1, 12.6, 11.6, 12.0, 12.2, 12.2, 12.5, 12.3, 13.1,
14.2, 12.1, 9.9, 11.0, 12.7, 12.6
13.1, 13.2, 12.6, 11.8, 12.4, 11.9, 12.1, 12.3, 11.9, 13.1,
14.3, 12.2, 11.0, 10.8, 13.1, 12.4
35.4, 36.8, 0, 38.9, 0, 0, 0, 36.6, 13.4, 13.8, 12.9, 12.7.
34.6, 34.3, 0, 30.8, 0, 29.3, 34.5, 34.4, 30.8
36.1, 36.6, 0, 0, 0, 0, 0, 36.1, 13.5, 13.7, 13.0, 12.8, 35.1,
34.3, 0, 31.0, 0, 29.1, 34.3, 34.1, 31.1
0, 0, 0, 30.1, 34.3, 29.9, 29.9, 0, 31.0, 32.3, 0, 0, 0
0, 0, 0, 30.6, 34.1, 30.2, 29.8, 0, 31.3, 32.7, 0, 0, 0
0, 0, 0, 0, 0
0, 39.8, 0, 0, 0
36.6, 0, 0, 35.7, 0, 36.1, 36.7, 0, 0, 0, 37.1, 35.3, 36.7,
36.6, 38.5, 0
36.4, 0, 0, 35.2, 0, 36.2, 36.7, 0, 0, 0, 37.3, 35.5, 36.8,
36.5, 38.2, 0
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pvl

Collection
One, 1st run
Collection
One, 2nd run
Collection
Two, 1st run
Collection
Two, 2nd run
Collection
Three, 1st run
Collection
Three, 2nd run
Collection
Four, 1st run
Collection
Four, 2nd run
Collection
One, 1st run
Collection
One, 2nd run

lukED

Collection
Two, 1st run
Collection
Two, 2nd run
Collection
Three, 1st run
Collection
Three, 2nd run
Collection
Four, 1st run
Collection
Four, 2nd run
Collection
One, 1st run

lukAB

Collection
One, 2nd run
Collection
Two, 1st run
Collection
Two, 2nd run

0, 0, 0, 43.7, 0, 40.7, 41.4, 0, 0, 0, 0, 0, 0, 0, 0, 0, 40.3,
39.8, 0, 42.6, 0
0, 0, 0, 0, 0, 42.2, 0, 0, 0, 0, 0, 0, 35.5, 0, 0, 36.1, 0, 0, 0,
0, 0
0, 0, 0, 0, 35.1, 0, 0, 0, 0, 42.1, 0, 40.6, 0
0, 0, 0, 0, 35.4, 0, 0, 0, 0, 41.9, 0, 40.3, 0
0, 0, 0, 0, 0
0, 0, 0, 0, 0
0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 39.9, 0, 0, 0, 0
0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 41.1, 0, 0, 0, 0
31.4, 31.8, 34.8, 14.4, 42.7, 33.0, 0, 34.0, 34.9, 35.5,
36.1, 32.8, 34.8, 34.8, 33.2, 36.8, 43.6, 14.4, 14.0, 13.1,
14.5
31.2, 31.9, 35.4, 14.8, 34.7, 34.0, 0, 33.6, 37.8, 34.4,
33.3, 34.7, 43.4, 34.2, 33.6, 37.6, 34.8, 14.5, 13.6, 13.5,
13.3
15.1, 16.9, 35.1, 32.6, 32.5, 33.1, 34.9, 15.1, 12.7, 11.9,
12.4, 13.1, 12.6
15.1, 17.0, 35.1, 33.0, 32.1, 33.0, 35.6, 15.1, 13.2, 12.9,
12.4, 13.1, 12.6
0, 40.1, 0, 0, 0
0, 39.9, 0, 0, 0
33.1, 32.0, 14.1, 13.4, 13.9, 12.3, 14.1, 14.5, 13.0, 28.8,
31.1, 32.0, 31.9, 31.8, 14.4, 14.3
33.2, 33.3, 14.3, 13.9, 14.1, 13.2, 14.4, 14.2, 13.6, 29.1,
30.0, 32.5, 32.0, 31.6, 14.3, 15.0
30.7, 31.2, 30.7, 14.9, 13.8, 14.2, 31.3, 33.5, 34.4, 33.0,
32.4, 29.7, 14.5, 33.8, 32.9, 31.7, 34.8, 14.6, 14.7, 13.8,
14.5
31.1, 30.9, 31.2, 14.6, 13.2, 13.6, 30.7, 33.1, 35.2, 32.3,
32.7, 29.8, 14.5, 32.8, 33.1, 31.3, 35.3, 14.6, 15.6, 14.0,
14.6
14.9, 16.3, 36.3, 33.0, 33.8, 33.6, 33.6, 14.3, 12.7, 11.6,
13.4, 13.4, 12.7
15.2, 16.1, 37.8, 33.4, 33.7, 33.5, 34.2, 14.0, 13.1, 11.4,
13.3, 13.1, 13.0
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Collection
Three, 1st run
Collection
Three, 2nd run
Collection
Four, 1st run
Collection
Four, 2nd run
Collection
One, 1st run
Collection
One, 2nd run

tst

Collection
Two, 1st run
Collection
Two, 2nd run
Collection
Three, 1st run
Collection
Three, 2nd run
Collection
Four, 1st run
Collection
Four, 2nd run
Collection
One, 1st run
Collection
One, 2nd run

hla

Collection
Two, 1st run
Collection
Two, 2nd run
Collection
Three, 1st run
Collection
Three, 2nd run
Collection
Four, 1st run
Collection
Four, 2nd run

0, 0, 0, 0, 14.4
0, 0, 0, 0, 14.0
0, 32.9, 13.3, 12.7, 13.3, 13.6, 13.6, 14.0, 14.0, 28.1,
32.8, 32.1, 13.2, 13.3, 14.5, 14.7
0, 33.1, 13.5, 12.5, 13.0, 13.5, 13.6, 14.0, 14.1, 28.2.
31.8, 32.0, 13.0, 13.3, 14.5, 14.6
31.1, 31.8, 31.1, 30.9, 32.0, 32.3, 15.0, 13.0, 0, 34.6,
31.3, 29.0, 30.1, 28.2, 13.8, 14.1, 14.7, 39.1, 37.3, 30.1,
30.8
29.5, 30.7, 30.9, 30.4, 31.4, 30.8, 15.5, 13.4, 0, 34.4,
30.5, 28.9, 29.9, 28.0, 13.9, 14.0, 14.8, 38.2, 35.4, 29.0,
29.1
30.9, 31.4, 14.1, 14.0, 31.8, 27.2, 30.1, 28.8, 30.1, 29.6,
31.0, 31.0, 40.7
31.0, 31.2, 14.2, 14.4, 32.6, 27.4, 30.2, 29.2, 31.6, 29.2,
29.9, 31.1, 40.0
17.0, 15.3, 18.5, 14.7, 0
16.5, 14.1, 18.1, 13.8, 0
14.5, 14.3, 30.1, 29.2, 31.3, 28.2, 31.1, 30.8, 29.7, 32.2,
29.1, 13.4, 33.5, 34.2, 29.1, 31.4
14.1, 14.5, 30.2, 29.1, 31.1, 28.6, 31.1, 30.9, 29.5, 32.4,
29.3, 13.4, 34.0, 34.3, 30.0, 30.9
16.2, 16.9, 17.5, 14.8, 13.9, 14.3, 16.9, 15.9, 36.7, 34.3,
15.4, 15.6, 15.4, 16.0, 16.2, 15.7, 16.2, 15.9, 14.2, 13.8,
13.9
15.9, 16.9, 16.8, 14.8, 24.0, 14.0, 16.7, 16.4, 35.1, 33.4,
15.1, 15.0, 14.9, 16.0, 15.6, 15.7, 15.8, 14.7, 15.0, 13.2,
13.9
16.1, 17.6, 16.4, 16.1, 17.2, 16.7, 16.3, 14.8, 13.8, 12.2,
12.9, 13.0, 13.6
15.5, 17.2, 15.8, 15.9, 16.7, 16.0, 15.8, 14.7, 12.9, 12.2,
12.6, 13.1, 12.7
17.1, 15.6, 17.3, 14.0, 16.9
16.8, 15.6, 17.2, 13.9, 15.8
17.1, 16.7, 14.6, 13.3, 13.6, 13.9, 14.1, 14.0, 15.5, 16.9,
17.1, 15.8, 12.5, 12.3, 14.4, 14.6
17.3, 15.9, 15.1, 13.5, 13.5, 13.2, 15.1, 15.5, 16.1, 16.6,
16.9, 16.2, 12.4, 12.5, 14.4, 14.5
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Collection
One, 1st run
Collection
One, 2nd run

hlb

Collection
Two, 1st run
Collection
Two, 2nd run
Collection
Three, 1st run
Collection
Three, 2nd run
Collection
Four, 1st run
Collection
Four, 2nd run
Collection
One, 1st run
Collection
One, 2nd run

hld

sea

Collection
Two, 1st run
Collection
Two, 2nd run
Collection
Three, 1st run
Collection
Three, 2nd run
Collection
Four, 1st run
Collection
Four, 2nd run
Collection
One, 1st run
Collection
One, 2nd run
Collection
Two, 1st run

30.6, 31.5, 31.0, 14.3, 13.4, 13.5, 14.0, 13.7, 33.6, 33.4,
29.7, 27.4, 13.9, 27.2, 12.9, 13.3, 13.6, 14.4, 14.7, 13.3,
13.6
29.5, 29.4, 31.7, 13.9, 12.6, 12.8, 13.5, 14.4, 0, 42.8,
38.5, 35.4, 19.4, 31.0, 13.5, 13.4, 12.9, 14.2, 15.2, 12.6,
13.5
15.4, 16.3, 12.7, 13.3, 14.0, 13.5, 12.9, 13.9, 12.0, 11.0,
11.9, 11.9, 11.6
15.1, 16.2, 13.2, 13.6, 14.1, 14.0, 12.7, 14.0, 12.3, 11.5,
12.0, 12.3, 11.4
17.4, 16.7, 16.3, 17.2, 0
16.8, 15.6, 16.2, 17.0, 0
14.2, 13.4, 13.0, 12.1, 13.0, 13.3, 13.5, 14.0, 13.6, 13.9,
14.8, 12.8, 12.3, 12.2, 13.6, 13.7
14.0, 13.5, 13.1, 12.0, 13.0, 13.5, 13.8, 13.9, 13.5, 14.1,
14.8, 12.7, 12.3, 12.3, 13.5, 13.8
14.7, 15.2, 15.8, 15.7, 14.9, 15.3, 15.6, 13.9, 37.9, 33.6,
13.9, 13.9, 15.9, 14.3, 14.6, 14.3, 15.0, 16.2, 14.6, 14.6,
14.7
14.4, 15.3, 15.7, 15.6, 14.8, 14.9, 15.5, 15.0, 34.9, 32.1,
13.7, 13.8, 15.3, 14.1, 14.3, 14.5, 14.3, 15.2, 15.7, 14.1,
14.8
15.9, 17.7, 14.6, 14.4, 15.4, 15.3, 14.9, 15.3, 13.7, 13.3,
13.8, 14.0, 14.1
15.7, 17.5, 14.3, 14.5, 15.6, 15.3, 14.9, 15.5, 13.8, 13.5,
13.7, 14.4, 13.6
15.2, 13.3, 16.1, 14.9, 15.0
16.0, 14.0, 16.5, 15.3, 15.5
15.5, 14.2, 14.2, 13.9, 14.1, 14.0, 14.3, 15.1, 14.7, 15.6,
16.6, 14.7, 13.3, 13.4, 14.9, 15.0
15.3, 15.0, 15.1, 13.9, 14.0, 14.2, 14.0, 14.3, 14.4, 15.2,
15.5, 14.7, 13.4, 13.6, 14.6, 14.8
9.9, 10.3, 11.3, 30.2, 36.1, 33.9, 32.9, 30.7, 0, 0, 30.4,
27.5, 14.1, 27.2, 12.6, 12.9, 12.9, 26.9, 34.3, 0, 30.6
11.6, 11.1, 12.1, 30.5, 32.3, 32.8, 32.5, 29.4, 0, 31.1,
34.1, 32.3, 14.1, 35.2, 14.2, 13.3, 13.8, 27.9, 33.8, 34.3,
30.9
15.4, 17.9, 31.7, 28.8, 13.3, 12.6, 12.5, 25.4, 34.4, 27.7,
33.5, 33.2, 34.3
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seb

sec

Collection
Two, 2nd run
Collection
Three, 1st run
Collection
Three, 2nd run
Collection
Four, 1st run
Collection
Four, 2nd run
Collection
One, 1st run
Collection
One, 2nd run
Collection
Two, 1st run
Collection
Two, 2nd run
Collection
Three, 1st run
Collection
Three, 2nd run
Collection
Four, 1st run
Collection
Four, 2nd run
Collection
One, 1st run
Collection
One, 2nd run
Collection
Two, 1st run
Collection
Two, 2nd run
Collection
Three, 1st run
Collection
Three, 2nd run
Collection
Four, 1st run
Collection
Four, 2nd run

15.5, 16.2, 31.5, 29.1, 14.6, 12.7, 12.6, 25.7, 32.4, 31.9,
32.4, 31.8, 32.4
16.1, 15.5, 17.3, 14.4, 0
16.5, 14.9, 17.0, 15.2, 0
0, 0, 0, 37.7, 0, 0, 37.1, 35.0, 36.6, 14.3, 16.0, 15.5, 35.0,
37.2, 0, 35.5
0, 0, 0, 36.0, 0, 36.5, 36.2, 36.1, 37.2, 15.3, 15.6, 15.7,
35.2, 36.0, 36.4, 35.1
0, 41.1, 0, 0, 0, 0, 39.7, 43.4, 41.5, 42.3, 44.4, 0, 0, 0, 0,
42.7, 0, 0, 0, 43.9, 43.3
0, 40.6, 0, 0, 0, 0, 39.9, 40.7, 43.2, 42.1, 0, 0, 0, 0, 0,
43.6, 0, 0, 0, 42.9, 43.3
42.8, 0, 38.5, 40.7, 0, 41.4, 42.2, 44.3, 40.7, 41.3, 42.4,
41.0, 38.6
43.1, 0, 0, 0, 0, 41.7, 42.1, 43.2, 36.2, 35.9, 35.0, 44.1,
34.0
0, 0, 0, 0, 15.1
0, 0, 0, 0, 15.3
0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0
37.9, 0, 0, 0, 0, 35.5, 37.2, 0, 0, 0, 0, 0, 0, 0, 0, 0
38.2, 0, 0, 0, 0, 0, 0, 36.5, 0, 34.7, 13.7, 13.9, 0, 37.9, 0,
37.9, 37.5, 33.3, 37.1, 0, 42.9, 36.9, 37.0
39.4, 0, 0, 0, 0, 0, 0, 37.5, 0, 34.2, 34.1, 14.2, 14.6, 0,
38.5, 37.6, 38.6, 37.4, 41.6, 42.3, 37.2, 37.1
0, 0, 40.7, 44.2, 0, 0, 41.1, 41.4, 0, 36.9, 36.0, 37.7, 13.7
0, 0, 41.0, 0, 0, 0, 41.0, 42.6, 0, 36.5, 36.4, 37.9, 13.5
0, 0, 0, 0, 0
0, 0, 0, 0, 0
0, 0, 0, 0, 0, 0, 37.9, 40.1, 0, 0, 0, 0, 41.0, 0, 0, 38.7
0, 0, 0, 0, 0, 0, 37.6, 40.3, 0, 0, 0, 0, 41.3. 0, 0, 38.4
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sed

see

eta

Collection
One, 1st run
Collection
One, 2nd run
Collection
Two, 1st run
Collection
Two, 2nd run
Collection
Three, 1st run
Collection
Three, 2nd run
Collection
Four, 1st run
Collection
Four, 2nd run
Collection
One, 1st run
Collection
One, 2nd run
Collection
Two, 1st run
Collection
Two, 2nd run
Collection
Three, 1st run
Collection
Three, 2nd run
Collection
Four, 1st run
Collection
Four, 2nd run
Collection
One, 1st run
Collection
One, 2nd run
Collection
Two, 1st run
Collection
Two, 2nd run
Collection
Three, 1st run

0, 0, 0, 0, 0, 41.0, 0, 44.0, 0, 35.6, 34.1, 0, 0, 0, 0, 0,
35.1, 0, 42.5, 0, 35.2
0, 0, 0, 0, 0, 41.4, 0, 44.8, 0, 36.1, 33.9, 0, 0, 0, 0, 0,
35.3, 0, 43.0, 0, 35.6
0, 0, 0, 0, 43.5, 0, 0, 0, 34.9, 32.6, 34.2, 35.3, 35.7
0, 0, 0, 0, 0, 0, 0, 0, 35.0, 32.3, 34.4, 35.7, 36.0
0, 0, 0, 0, 0
0, 0, 0, 0, 0
0, 0, 12.2, 33.5, 33.1, 0, 34.9, 0, 0, 33.6, 33.9, 33.8, 0, 0,
0, 33.3
0, 0, 12.3, 33.4, 33.0, 0, 0, 0, 0, 34.1, 34.2, 33.9, 0, 0, 0,
33.2
42.5, 0, 0, 0, 0, 42.2, 0, 35.2, 0, 0, 0, 0, 0, 0, 0, 43.2, 0, 0,
41.7, 41.9, 0
33.7, 34.3, 35.2, 0, 0, 0, 0, 34.3, 35.2, 0, 34.2, 31.7, 0,
42.3, 35.2, 35.3, 41.2, 33.5
0, 0, 0, 41.1, 0, 0, 0, 0, 39.6, 38.8, 0, 0, 0
0, 0, 0, 43.0, 0, 0, 0, 0, 38.9, 38.6, 0, 0, 0
0, 0, 0, 0, 0
0, 0, 0, 0, 0
33.2, 0, 0, 0, 0, 0, 0, 0, 35.5, 0, 0, 0, 0, 0, 0, 0
33.7, 0, 0, 0, 0, 0, 0, 0, 34.9, 0, 0, 0 0, 0, 34.8, 0
42.6, 42.9, 0, 43.4, 42.8, 0, 0, 42.9, 43.3, 40.7, 41.2,
42.3, 0, 43.7, 42.8, 43.9, 0, 42.8, 0, 42.3, 42.1
42.0, 0, 42.3, 41.4, 40.7, 42.4, 0, 42.8, 42.2, 42.9, 39.5,
40.1, 43.1, 42.4, 0, 42.3, 44.3, 41.4, 43.3, 43.3, 41.1
0, 0, 41.7, 0, 0, 0, 0, 0, 40.7, 39.5, 0, 0, 40.5
0, 0, 0, 0, 0, 0, 0, 0, 41.0, 39.1, 0, 0, 40.4
0, 0, 0, 0, 0
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Collection
Three, 2nd run
Collection
Four, 1st run
Collection
Four, 2nd run
Collection
One, 1st run
Collection
One, 2nd run

hlgA

Collection
Two, 1st run
Collection
Two, 2nd run
Collection
Three, 1st run
Collection
Three, 2nd run
Collection
Four, 1st run
Collection
Four, 2nd run
Collection
One, 1st run
Collection
One, 2nd run

hlgC

Collection
Two, 1st run
Collection
Two, 2nd run
Collection
Three, 1st run
Collection
Three, 2nd run
Collection
Four, 1st run
Collection
Four, 2nd run

0, 0, 0, 0, 0
0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 39.1, 0, 0, 0, 0
0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 39.1, 0, 0, 0, 0
13.4, 13.6, 14.4, 14.5, 13.5, 13.5, 13.8, 13.3, 32.5, 29.2,
13.1, 11.2, 14.6, 11.6, 13.1, 13.3, 13.8, 14.9, 14.5, 12.7,
13.0
13.3, 13.6, 14.1, 14.5, 13.6, 13.3, 14.0, 13.4, 36.1, 30.0,
13.2, 11.6, 14.6, 11.4, 13.0, 13.3, 13.7, 15.0, 14.6, 12.5,
13.0
15.1, 16.6, 12.5, 12.4, 13.8, 13.2, 13.1, 13.2, 11.8, 11.6,
11.5, 11.9, 12.0
15.1, 16.3, 12.5, 13.2, 13.8, 13.2, 14.1, 14.9, 12.3, 11.2,
11.5, 12.2, 12.2
16.0, 16.5, 15.3, 17.4, 14.9
16.1, 16.5, 15.8, 17.3, 14.0
12.2, 13.4, 14.9, 14.3, 15.2, 11.1, 11.9, 12.3, 13.4, 13.2,
14.1, 11.1, 11.0, 12.5, 14.3, 13.0
12.2, 12.8, 14.9, 15.4, 15.3, 11.2, 12.5, 12.3, 12.8, 13.7,
13.4, 12.2, 11.9, 11.7, 13.3, 13.5
13.5, 14.0, 14.2, 13.6, 13.6, 13.6, 14.3, 14.3, 33.4, 30.4,
13.5, 11.3, 15.3, 11.6, 13.5, 12.7, 13.1, 14.3, 14.6, 13.0,
13.0
13.3, 14.1, 14.2, 13.7, 14.1, 13.7, 14.2, 14.3, 34.0, 31.4,
13.4, 11.0, 15.3, 11.6, 13.3, 12.5, 13.1, 14.1, 14.7, 12.7,
13.2
13.7, 15.9, 12.0, 12.0, 11.3, 12.9, 13, 13.5, 11.6, 11.43,
11.6, 11.9, 11.5
14.0, 16.2, 12.1, 12.3, 11.5, 13.2, 13.5, 13.6, 11.2, 11.5,
11.0, 12.6, 11.3
15.1, 16.4, 15.8, 17.6, 15.1
16.3, 16.8, 15.3, 17.2, 15.5
14.1, 15.0, 15.3, 16.5, 16.2, 15.3, 13.2, 14.8, 14.2, 14.5,
13.8, 16.7, 15.1, 15.0, 14.1, 14.0
15.3, 14.1, 16.8, 16.3, 16.5, 14.0, 14.2, 15.1, 14.0, 13.8,
13.6, 15.0, 15.9, 15.7, 14.3, 13.9

63

